GITR & GITR Ligand Immune Checkpoint Pathway: Description
Tumor Necrosis Factor receptor super family members (TNFRSFs) play an important role in the immune responses and inflammatory reactions. One of TNFRSFs, TNFRSF18 (GITR), a recently identified novel tumor suppressor on chromosome 1p36, loss of which might be highly related to pathogenesis in differential human cancers. It has been reported that GITR / TNFRSF18 deficiency could result in increased cell proliferation and reduced apoptosis in human Multiple Myeloma (MM). NF-κB transcription factors play a key role in the survival and proliferation of many kinds of B-cell tumors, especially for multiple myeloma. It has also been shown that mutations involved in the NF-κB pathway are present in 15–20% of MM tumors. These mutations can lead to activation of the canonical and non-canonical NF-κB pathway. Therefore, targeting the NF-κB pathway is an attractive therapy approach for MM. In previous report, it has been shown that GITR / TNFRSF18 expression also impacts the NF-κB activation in response to GITR Ligand/TNFSF18. These findings above indicate that GITR / TNFRSF18 might also be important to drug response through modulating NF-κB pathway since NF-κB inhibitors were developed to treat MM patients in the past years.
It has also been shown that GITR & GITR Ligand immune checkpoint pathway can regulate immunity by potentiating CD4+ and CD8+ effector T cell function while modulating regulatory T cells. In tumor bearing mice, treatment with the GITR agonist monoclonal antibody mDTA-1 has been shown to increase intratumoral effector T cell function and decrease regulatory T cell stability, culminating in effective tumor regression.
GITR & GITR Ligand Immune Checkpoint Pathway: Reference
Brunn ND et al. The Role of Anti-drug Antibodies in the Pharmacokinetics, Disposition, Target Engagement, and Efficacy of a GITR Agonist Monoclonal Antibody in Mice. J Pharmacol Exp Ther. 2015.
GITR & GITR Ligand Immune Checkpoint Pathway: Relatives
|Co-inhibitory immune checkpoint pathways||Co-stimulatory immune checkpoint pathways|
|PD1 & PD-L1 immune checkpoint pathway||CD266 & CD155 immune checkpoint pathway|
|CTLA-4 & CD80 (CD86) immune checkpoint pathway||CD40 & CD40L immune checkpoint pathway|
|B7-H3 / CD276 immune checkpoint pathway||OX40 & OX40L immune checkpoint pathway|
|B7-H4 / B7S1 / B7x immune checkpoint pathway||HVEM & LIGHT immune checkpoint pathway|
|HVEM & BTLA immune checkpoint pathway||CD28 & CD80 (CD86) immune checkpoint pathway|
|HVEM & CD160 immune checkpoint pathway||CD27 & CD70 immune checkpoint pathway|
|LAG3 / CD223 / Lymphocyte activation gene 3 immune checkpoint pathway||4-1BB & 4-1BBL immune checkpoint pathway|
|Galectin-9 & TIM-3 immune checkpoint pathway||ICOS & ICOS Ligand immune checkpoint pathway|
|Indoleamine 2,3-dioxygenase/IDO immune checkpoint pathway|
|VISTA / B7-H5 / GI24 immune checkpoint pathway|
|CEACAM1 / CD66a immune checkpoint pathway|
|SIRP alpha & CD47 immune checkpoint pathway|
|2B4 & CD48 immune checkpoint pathway|
|TIGIT & CD155 immune checkpoint pathway|